| Literature DB >> 36119197 |
Ritu Sharma1, Shikha Seth1, Pinky Mishra1, Neha Mishra1, Rakhee Sharma1, Monika Singh1.
Abstract
The course of coronavirus disease-2019 (COVID-19) in pregnancy is unpredictable with outcome trends ranging from milder disease with zero mortality to severe forms and deaths in different parts of the world. We did a comprehensive review of the literature to understand maternal deaths due to COVID-19 in detail. The search was conducted in the PubMed, Embase, and Google Scholar databases, using the keywords "maternal mortality", "maternal death", "COVID-19", "septic shock" and "DIC". The search included original articles, review articles, case reports published till date. We found varying case fatality rates ranging from 0.1% to 12.9%. There are various predictors of maternal death, notably the presence of symptoms, comorbidities, severe disease with cytokine storm and multi-organ dysfunction. We also report higher maternal deaths from low-resource regions owing to gaps in expected and delivered maternal care. While reviewing our institutional data, we found 3 maternal deaths related to COVID-19 in pregnancy. We discussed our experience at our institute of three COVID-19 related maternal mortalities to add evidence to the present data. Most maternal deaths occurred in postpartum period. Late referral, loss to follow-up and inadequate care were important determinants of maternal mortality. We concluded that pregnancy cases with or without complications must be considered high risk and addressed judiciously beginning from infection prevention, early diagnosis, disease categorization, and multidisciplinary approach of management to prevent morbidity and mortality. We strongly suggest strengthening the health care delivery system to save pregnant women from dying, particularly in low-resource countries. Copyright:Entities:
Keywords: ARDS; COVID-19; DIC; cytokine storm; maternal deaths; maternal mortality; septic shock; venous thromboembolism
Year: 2022 PMID: 36119197 PMCID: PMC9480707 DOI: 10.4103/jfmpc.jfmpc_384_21
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Clinical profile of two cases
| Parameters | Case 1 | Case 2 |
|---|---|---|
| Age | 25 yr | 32 yr |
| Parity | G1P0 | G1P0 |
| Gestation | singleton gestations at 26 weeks | Diamniotic Dichorionic IVF conceived twin gestation at 36 weeks 4 days |
| Symptoms | Shortness of breath, fever | Asymptomatic |
| q-SOFA score on admission | 1 | 0 |
| Co morbidities | Bronchial Asthma | None |
| Poor prognostic factors | Raised TLC, Lymphopenia, Neutrophilia | Raised TLC, CRP, Neutrophilia, Raised |
| Delivered | No | Yes - Caesarean Section |
| Operated | No | Yes (twice- caesarean and laparotomy) |
| O2 support | Yes | No |
| Ventilator support | Yes, antepartum on Day 6 | Yes, post-partum day 1 |
| Low molecular weight heparin | Yes | No |
| Plasma therapy | Yes | No |
| Probable cause of death | Acute respiratory failure secondary to COVID pneumonia with ARDS | Venous thromboembolism with Multi organ dysfunction syndrome and Sepsis |
| Hospital stay | 5 days 6 h | 1 day 17 h |
Biochemical and radiological profile of two cases
| Investigations with reference values | Day 1 | Day 6 | Day 1 | Day 2 |
|---|---|---|---|---|
| Hemoglobin (11.5-15 gm/dl) | 11.3 | 10.7 | 13.2 | 10 |
| Total Leucocyte Count (4000-10,000 cell/mm3) | 12300 | 15300 | 20200 | 22000 |
| Differential Leucocyte Count | ||||
| Polymorphs (P 40-80%) | 82 | 85 | 71 | 84 |
| Lymphocytes (L 20-40%) | 11 | 9 | 20 | 18 |
| Eosinophils (E 1-6%) | 5 | 4 | 7 | 6 |
| Monocytes (M 2-10%) | 2 | 2 | 2 | 2 |
| Platelet (1.5-4.5 lac/mm3) | 2.77 | 3.28 | 1.4L | 1.4L |
| Blood Sugar (70-140 mg/dl) | 109.6 | - | 90 | 49.4 |
| Urine routine microscopy | No albumin, sugar or ketone | Glucose + | No albumin, sugar or ketone | No albumin, sugar or ketone |
| Urea (13-43 mg/dl) | 16.0 | 24.7 | 74 | 80 |
| Creatinine (0.6-1.2 mg/dl) | 0.77 | 0.7 | 3.08 | 3.5 |
| Uric acid (2.6-6.0 mg/dl) | 4.6 | 2.3 | 9.6 | 9 |
| Bilirubin Total (0.3-1.2 mg/dl) | 0.6 | 0.65 | 9.7 | 9.5 |
| Direct (<0.2 mg/dl) | 6.8 | 6.7 | ||
| Indirect (0.2-0.7 mg/dl) | 2.94 | 2.8 | ||
| Aspartate aminotransferase (<40 IU/L) | 76 | 144 | 250 | 258 |
| Alanine aminotransferase (<40 IU/L) | 62 | 133.5 | 201 | 220 |
| Alkaline phosphatise (60-240 IU/L) | 241.7 | 243.5 | 900 | 978 |
| Proteins (3.8-5.5 mg/dl) | 4 | 4.1 | 3.3 | 3.2 |
| Prothrombin Time | 14.9 | 14.2 | 14.8 | 15.3 |
| Activated Partial Thromboplastin time (28.69-41.89) | 32.5 | 31.2 | 39.3 | 42.5 |
| International normalized ratio INR | 1.10 | 1.05 | 1.09 | 1.13 |
| D-Dimer (<500 ng/ml) | 2847 | 3500 | 10,000 | >10,000 |
| CRP (<3 mg/L) | 1 | 2 | 37.6 | 40 |
| Lactate Dehydrogenase LDH (125-220 U/L) | 772 | 792 | 597 | 655 |
| Ferritin (15-150 ng/ml) | 72.8 | 65 | 66.54 | 74 |
| Arterial blood gas analysis (ABG) | Mild respiratory alkalosis | Severe metabolic acidosis | Not done | Severe metabolic acidosis with hypoxia with hyperkalemia |
| Chest X ray | Patchy alveolar opacities bilateral mid and lower lung zones ? viral pneumonia | Day 4 Patchy confluent opacities bilateral lungs ?ARDS | Apparently normal |
COVID-19 related maternal morbidity and mortality among various studies
| Authors | Study type | Total no. of COVID-19 Pregnant women | Percentage of pregnant patients with severe/critical COVID-19 | Total no. of maternal COVID-19 deaths; Case fatality rate | Comments |
|---|---|---|---|---|---|
| Papapanou | Systematic review and meta-analysis | - | 3-10% | <2% | This study attributed contradictory maternal rates across the world to differing healthcare infrastructure in various countries. |
| Chi | Systematic review and meta-analysis | 230 | 17.5% | 1; 0.43% | 15 out of 20 studies included in this review were from China. So, the findings of this study can’t be generalised. |
| Kim | Systematic review and meta-analysis) | 85 (all ICU cases) | 100% | 11; 12.9% | 1. The unusually high case fatality rate is because of including only patients admitted to ICU. |
| 2. This study emphasizes the importance of recognizing maternal disease severity and associated intervention timely to decrease the risk of death in critically ill pregnant patients. | |||||
| Taro | Systematic review and meta-analysis | 1100 | 8% | 5; 0.45% | This study demonstrated case fatality rate in pregnant and non-pregnant females to be the same. However, the studies included exhibited significant heterogeneities. |
| Allotey | Living Systematic review and meta-analysis | 11,432 | 13% | 73; 0.1% | They observed increased incidence of asymptomatic disease, ICU admission and invasive ventilation in pregnant patients as compared to non-pregnant women. |
| Khalil | Systematic review and meta-analysis | 2567 | 7% | 43; 0.9% | Only studies with sample size >15 included. Small case series/case reports were excluded |
| Di Mascio | Multinational retrospective cohort study from WAPM* | 388 | 11% | 3; 0.8% | 1. There was no statistically significant difference in the maternal mortality and morbidity observed between different regions. |
| 2. The presence of COVID-19 symptoms was only predictor of primary outcome (composite measure of maternal mortality and morbidity). | |||||
| 3. Non-inclusion of low-income countries limits the generalization of findings. | |||||
| Marquez | Research | 308 | - | 7; 2.3% | 1. They highlighted the gap between expected and delivered level of maternity care. |
| 2. The role of COVID-19 as a direct or indirect cause of mortality was not clear. | |||||
| Takemoto | Research | 978 (all ARDS cases) | 100% | 124; 12.4% | 1. The disturbing high case fatality rate is due to inclusion of only COVID-19 pregnant women with ARDS. |
| 2. Authors have missed the opportunity to compare this result to the non-pregnant women affected with COVID-19 induced ARDS. | |||||
| 3. This case fatality rate may not be true as 30% cases were not included due to incomplete data. | |||||
| Hantoushzadeh | Case Series | 9 | 100% | 7; 77% | Mortality rate for severe cases cannot be generalized from this study as it is not a surveillance cohort. However, it is one of the first case series to show that maternal mortality due to COVID-19 is not zero. |
| Antoun | Prospective cohort study | 23 | 34.8% | 1; 4.3% | This study presents data from early phase of the pandemic from UK with 70% of the infected patients from Asian background. |
* (World Association of Perinatal Medicine) working group